143 related articles for article (PubMed ID: 6118669)
21. Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes.
Kefford RF; Fox RM
Br J Haematol; 1982 Apr; 50(4):627-36. PubMed ID: 6978147
[TBL] [Abstract][Full Text] [Related]
22. Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin).
Dang-Vu AP; Olsen EA; Vollmer RT; Greenberg ML; Hershfield MS
J Am Acad Dermatol; 1988 Oct; 19(4):692-8. PubMed ID: 3263401
[TBL] [Abstract][Full Text] [Related]
23. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Mitchell BS; Koller CA; Kelley WN
Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
[No Abstract] [Full Text] [Related]
24. Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms.
Spiers AS; Ruckdeschel JC; Horton J
Scand J Haematol; 1984 Feb; 32(2):130-4. PubMed ID: 6608139
[TBL] [Abstract][Full Text] [Related]
25. The treatment of hairy cell leukemia (HCL) with pentostatin (2'-deoxycoformycin, dCF).
Spiers AS; Parekh SJ
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():173-5. PubMed ID: 2653498
[No Abstract] [Full Text] [Related]
26. T-cell chronic lymphocytic leukaemia: anomalous cell markers, variable morphology, and marked responsiveness to pentostatin (2'-deoxycoformycin).
Spiers AS; Davis MP; Levine M; Li CY; Mangan KF; Mazza JJ; Neu LT; O'Brien J; Rauch AE; Wiltsie JC
Scand J Haematol; 1985 Jan; 34(1):57-67. PubMed ID: 2578689
[TBL] [Abstract][Full Text] [Related]
27. Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia.
Plunkett W; Nowak B; Feun LG; Benjamin RS; Keating M; Freirich EJ
Adv Exp Med Biol; 1984; 165 Pt B():345-50. PubMed ID: 6372382
[No Abstract] [Full Text] [Related]
28. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
29. The biochemical and clinical consequences of 2'-deoxycoformycin in T cell chronic lymphocytic leukaemia.
Hallam LJ; Van der Weyden MB; Ackland SP; Bagnara AS; Whiteside MG
Scand J Haematol; 1984 Jan; 32(1):55-64. PubMed ID: 6607510
[TBL] [Abstract][Full Text] [Related]
30. Relationship of 5'-nucleotidase activity and antileukemic effect in 2'-deoxycoformycin therapy.
Wortmann RL; Holcenberg J; Poplack DG
Cancer Treat Rep; 1982 Feb; 66(2):387-90. PubMed ID: 6275991
[No Abstract] [Full Text] [Related]
31. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Ho AD; Thaler J; Mandelli F; Lauria F; Zittoun R; Willemze R; McVie G; Marmont AM; Prümmer O; Stryckmans P
J Clin Oncol; 1989 Oct; 7(10):1533-8. PubMed ID: 2789273
[TBL] [Abstract][Full Text] [Related]
32. Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with alpha-2-interferon and deoxycoformycin.
Thaler J; Denz H; Dietze O; Gastl G; Ho AD; Gattringer C; Greil R; Lechleitner M; Huber C; Huber H
Leuk Res; 1989; 13(5):377-83. PubMed ID: 2787447
[TBL] [Abstract][Full Text] [Related]
33. Successful remission induction with deoxycoformycin in elderly patients with T-helper prolymphocytic leukaemia.
el'Agnaf MR; Ennis KE; Morris TC; Robertson JH; Markey G; Alexander HD
Br J Haematol; 1986 May; 63(1):93-104. PubMed ID: 2939873
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo effect of deoxycoformycin in human T cell leukemia.
Yu AL; Kung FH; Bakay B; Nyhan WL
Adv Exp Med Biol; 1979; 122B():373-9. PubMed ID: 397762
[No Abstract] [Full Text] [Related]
35. Treatment of multiple myeloma with deoxycoformycin.
Belch AR; Henderson JF; Brox LW
Cancer Chemother Pharmacol; 1985; 14(1):49-52. PubMed ID: 3871175
[TBL] [Abstract][Full Text] [Related]
36. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
Kefford RF; Fox RM
Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
[No Abstract] [Full Text] [Related]
37. 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
O'Dwyer PJ; Wagner B; Leyland-Jones B; Wittes RE; Cheson BD; Hoth DF
Ann Intern Med; 1988 May; 108(5):733-43. PubMed ID: 3282467
[TBL] [Abstract][Full Text] [Related]
38. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
[No Abstract] [Full Text] [Related]
39. Pentostatin in the treatment of advanced hairy cell leukemia.
Kraut EH; Bouroncle BA; Grever MR
J Clin Oncol; 1989 Feb; 7(2):168-72. PubMed ID: 2783731
[TBL] [Abstract][Full Text] [Related]
40. The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy.
Grever MR; Siaw MF; Jacob WF; Neidhart JA; Miser JS; Coleman MS; Hutton JJ; Balcerzak SP
Blood; 1981 Mar; 57(3):406-17. PubMed ID: 6970050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
